Continued access to ATH434 for past study participants
Part of Brain & nervous system clinical trials.
This trial offers continued access to the study drug ATH434 for people in France who finished a previous study (ATH434-201) and may still benefit from treatment. It aims to provide ongoing care while monitoring safety and effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the ATH434-201 study in France.
- Your doctor must believe you may benefit from continuing treatment with ATH434.
- You cannot have stopped ATH434 treatment early for any reason in the previous study.
- You must not have a serious medical or mental health condition that would make this treatment unsafe or not helpful, according to your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug TEV-56286 continues to work for multiple system atrophy (a rare brain disorder). It is for people who already completed a previous study of the same drug.
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
This trial gives patients with Fabry disease who took part in a previous study the chance to continue receiving the study treatment, lucerastat, after that study ends. It aims to provide uninterrupted care while longer-term safety and effects are monitored.
This study is an extension of a previous trial (study 301) for adults with a heart condition called transthyretin amyloid cardiomyopathy. It aims to evaluate the long-term safety and effectiveness of an investigational drug (ALXN2220). Participants who completed the earlier study without stopping the drug or withdrawing consent may be eligible to continue receiving the treatment.
This trial is for people with Parkinson's disease or multiple system atrophy (parkinsonian type) who took part in an earlier AB-1005 study. It will continue to monitor your health over time to learn more about the treatment's long-term effects.
This study is testing a medication called acoramidis for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It aims to see how well the treatment works in a real-world setting in France.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.